Study Summary
This trial is studying a new way of doing an HCT: using drugs to lower the activity of the body's immune system before transplanting healthy stem cells to replace diseased or damaged cells.
- Beta Thalassemia
- Thalassemia
- Sickle Cell Disease
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: 1 year
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
Participants with Sickle Cell Disease or β-Thalassemia
1 of 1
Experimental Treatment
24 Total Participants · 1 Treatment Group
Primary Treatment: Participants with Sickle Cell Disease or β-Thalassemia · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 2 - 50 · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Does this research project accept individuals aged 45 or older as participants?
"Per the trial's criteria, individuals between 2 and 50 years old are eligible for enrollment." - Anonymous Online Contributor
May I be eligible to join this experiment?
"Eligibility to this medical trial necessitates that patients have thalassemia and are between 2-50 years old. The goal is to recruit around 24 participants for the clinical study." - Anonymous Online Contributor
Are any enrollees being welcomed into this research initiative currently?
"Correct. Clinicaltrials.gov testifies that this trial is actively enrolling patients; it was initially posted on February 9th, 2023 and the most recent edit occurred on the 17th of February 2023. The study requires 24 individuals to be selected from 6 different medical sites." - Anonymous Online Contributor
How many centers are responsible for coordinating the progress of this trial?
"The current trial is recruiting out of 6 sites, including Montvale, Middletown and Commack. It would be beneficial to select the closest one in order to reduce travel costs incurred when joining this study." - Anonymous Online Contributor
What is the maximum capacity for participants in this experiment?
"Affirmative. Clinicaltrials.gov's records demonstrate that this clinical trial, which was initially advertised on February 9th 2023 is actively seeking participants. Around 24 people must be enrolled from 6 associated medical centres." - Anonymous Online Contributor
What health risks do those with Sickle Cell Disease or β-Thalassemia face?
"Our team at Power has assessed the safety of individuals suffering from Sickle Cell Disease or β-Thalassemia as a 2 due to its current Phase 2 status. While there is evidence affirming some measure of protection, no data exists in support of efficacy." - Anonymous Online Contributor